Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

References

1. Combs K, Cox K. Clinical outcomes involving patients that develop septic arthritis with methicillin sensitive Staphylococcus aureus versus methicillin resistant Staphylococcus aureus. J Orthop 2018; 15:9–12 [View Article]
   [Google Scholar]
2. European Centre for Disease Prevention and Control 2014; Annual epidemiological report: antimicrobial resistance and healthcare-associated infections. www.ecdc.europa.eu on May 8, 2019
3. Centers for Disease Control and Prevention Methicillin-Resistant Staphylococcus aureus (MRSA) infections.
4. Huang DB, Dryden M, Iclaprim DM. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. Future Microbiol 2018; 13:957–969 [View Article]
   [Google Scholar]
5. Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis 2018; 66:1222–1229 [View Article]
   [Google Scholar]
6. Holland TL, O'Riordan W, McManus A, Shin E, Borghei A et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother 2018; 62:e02580–17 [View Article]
   [Google Scholar]
7. Huang DB, Magnet S, De Angelis S, Holland TL, File TM et al. Surveillance of iclaprim activity: in vitro susceptibility of gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. Diagn Microbiol Infect Dis 2019; 93:154–158 [View Article]
   [Google Scholar]
8. Guide for the care and use of laboratory animals. NIH Publications No. 8023, revised 1978
   [Google Scholar]
9. CLSI M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved standard: tenth edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
   [Google Scholar]
10. Gemmell CG, Goutcher SC, Reid R, Sturrock RD. Role of certain virulence factors in a murine model of Staphylococcus aureus arthritis. J Med Microbiol 1997; 46:208–213 [View Article]
    [Google Scholar]
11. Bremell T, Lange S, Svensson L, Jennische E, Gröndahl K et al. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum 1990; 33:1739–1744 [View Article]
    [Google Scholar]
12. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A. Experimental Staphylococcus aureus arthritis in mice. Infect Immun 1991; 59:2615–2623
    [Google Scholar]
13. Huang DB. A pharmacokinetic and pharmacodynamic evaluation of iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse abscess model. J Med Microbiol 2019; 68:77–80 [View Article]
    [Google Scholar]
14. Rydén C, Yacoub AI, Maxe I, Heinegård D, Oldberg A et al. Specific binding of bone sialoprotein to Staphylococcus aureus isolated from patients with osteomyelitis. Eur J Biochem 1989; 184:331–336 [View Article]
    [Google Scholar]
15. Bryant AE, Gomi S, Katahira E, Huang DB, Stevens DL. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus . J Med Microbiol 2019; 68:456–466 [View Article]
    [Google Scholar]
16. Huang DB, Park JH, Murphy TM. Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model. Eur J Clin Microbiol Infect Dis 2019; 38:409–412 [View Article]
    [Google Scholar]